Dexmedetomidine upregulates microRNA-185 to suppress ovarian cancer growth via inhibiting the SOX9/Wnt/β-catenin signaling pathway

References

• Hua F, Li C-H, Chen X-G, et al. Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade. Int J Mol Med. 2018;41(6):3485–3492.
   PubMed Web of Science ®Google Scholar
• Bareiss PM, Paczulla A, Wang H, et al. SOX2 expression associates with stem cell state in human ovarian carcinoma. Cancer Res. 2013;73:5544–5555.
   PubMed Web of Science ®Google Scholar
• Nikpayam E, Tasharrofi B, Sarrafzadeh S, et al. The role of long non-coding RNAs in ovarian cancer. Iran Biomed J. 2017;21(1):3–15.
   PubMedGoogle Scholar
• Ozga M, Aghajanian C, Myers-Virtue S, et al. A systematic review of ovarian cancer and fear of recurrence. Palliat Support Care. 2015;13:1771–1780.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu X, Li T, et al. Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer. Oncol Rep. 2017;37:3084–3092.
   PubMed Web of Science ®Google Scholar
• Varughese J, Cocco E, Bellone S, et al. High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody. Gynecol Oncol. 2011;122:171–177.
   PubMed Web of Science ®Google Scholar
• Weerink MAS, Struys M, Hannivoort LN, et al. Clinical pharmacokinetics and pharmacodynamics of dexmedetomidine. Clin Pharmacokinet. 2011;408(8):893–913.
   Google Scholar
• Mohta M, Kalra B, Sethi AK, et al. Efficacy of dexmedetomidine as an adjuvant in paravertebral block in breast cancer surgery. J Anesth. 2016;30:252–260.
   PubMed Web of Science ®Google Scholar
• Roberts SB, Wozencraft CP, Coyne PJ, et al. Dexmedetomidine as an adjuvant analgesic for intractable cancer pain. J Palliat Med. 2011;14:371–373.
   PubMed Web of Science ®Google Scholar
• Endesfelder S, Makki H, Von Haefen C, et al. Neuroprotective effects of dexmedetomidine against hyperoxia-induced injury in the developing rat brain. PLoS One. 2017;12(2):e0171498.
   PubMed Web of Science ®Google Scholar
• Wang W-X, Wu Q, Liang -S-S, et al. Dexmedetomidine promotes the recovery of neurogenesis in aged mouse with postoperative cognitive dysfunction. Neurosci Lett. 2018;677:110–116.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Jia S, Gao T, et al. Dexmedetomidine mitigate acute lung injury by inhibiting IL-17-induced inflammatory reaction. Immunobiology. 2018;223(1):32–37.
   PubMed Web of Science ®Google Scholar
• Ji J, Shi J, Budhu A, et al. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med. 2009;361(15):1437–1447.
   PubMed Web of Science ®Google Scholar
• Palma E, Gonzalez V, Grunholz D, et al. Tormenta de citoquinas: reacción adversa inhabitual por rituximab. Caso clínico. Rev Med Chil. 2017;145(2):260–263.
   PubMedGoogle Scholar
• Xie L, Zhang Z, Tan Z, et al. MicroRNA-124 inhibits proliferation and induces apoptosis by directly repressing EZH2 in gastric cancer. Mol Cell Biochem. 2014;392(1–2):153–159.
   PubMed Web of Science ®Google Scholar
• Liu C, Li G, Ren S, et al. miR-185-3p regulates the invasion and metastasis of nasopharyngeal carcinoma by targeting WNT2B in vitro. Oncol Lett. 2017;13(4):2631–2636.
   PubMed Web of Science ®Google Scholar
• Li S, Ma Y, Hou X, et al. MiR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells. Int J Clin Exp Pathol. 2015;8:11854–11862.
   PubMed Web of Science ®Google Scholar
• Xiang Y, Ma N, Wang D, et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene. 2014;33:378–386.
   PubMed Web of Science ®Google Scholar
• Lei Z, Shi H, Li W, et al. miR185 inhibits nonsmall cell lung cancer cell proliferation and invasion through targeting of SOX9 and regulation of Wnt signaling. Mol Med Rep. 2018;17:1742–1752.
   PubMed Web of Science ®Google Scholar
• Lu B, Fang Y, Xu J, et al. Analysis of SOX9 expression in colorectal cancer. Am J Clin Pathol. 2008;130:897–904.
   PubMed Web of Science ®Google Scholar
• Thomsen MK, Ambroisine L, Wynn S, et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010;70(3):979–987.
   PubMed Web of Science ®Google Scholar
• Raspaglio G, Petrillo M, Martinelli E, et al. Sox9 and Hif-2alpha regulate TUBB3 gene expression and affect ovarian cancer aggressiveness. Gene. 2014;542:173–181.
   PubMed Web of Science ®Google Scholar
• Ma F, Ye H, He HH, et al. SOX9 drives WNT pathway activation in prostate cancer. J Clin Invest. 2016;126:1745–1758.
   PubMed Web of Science ®Google Scholar
• Li F, Zhang L, Li W, et al. Circular RNA ITCH has inhibitory effect on ESCC by suppressing the Wnt/beta-catenin pathway. Oncotarget. 2015;6:6001–6013.
   PubMed Web of Science ®Google Scholar
• Ruan X, Liu A, Zhong M, et al. Silencing LGR6 attenuates stemness and chemoresistance via inhibiting Wnt/beta-Catenin signaling in ovarian cancer. Mol Ther Oncolytics. 2019;14:94–106.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhao B, Li X. Dexmedetomidine attenuates isoflurane-induced cognitive impairment through antioxidant, anti-inflammatory and anti-apoptosis in aging rat. Int J Clin Exp Med. 2015;8:17281–17288.
   PubMed Web of Science ®Google Scholar
• Abukiwan A, Nwaeburu CC, Bauer N, et al. Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-beta-driven progression of pancreatic cancer. Int J Oncol. 2019;54(1):53–64.
   PubMed Web of Science ®Google Scholar
• Xiao S, Li Y, Pan Q, et al. MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy. J Cell Biochem. 2019;120(3):2940–2953.
   PubMed Web of Science ®Google Scholar
• Guo YZ, Xie XL, Fu J, et al. SOX9 regulated proliferation and apoptosis of human lung carcinoma cells by the Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2018;22(15):4898–4907.
   PubMed Web of Science ®Google Scholar
• Liu S, Liu Y, Lu Q, et al. The lncRNA TUG1 promotes epithelial ovarian cancer cell proliferation and invasion via the WNT/beta-catenin pathway. Onco Targets Ther. 2018;11:6845–6851.
   Google Scholar
• Basuli D, Tesfay L, Deng Z, et al. Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene. 2017;36:4089–4099.
   PubMed Web of Science ®Google Scholar
• Heimisdottir M. [Unlocking the full potential of Landspitali University Hospital - Icelandic healthcare at a crossroads. An outsiders view from McKinsey and Company[Editorial]]. Laeknabladid. 2016;102:425.
   PubMedGoogle Scholar
• Shanbehzadeh S, Salavati M, Talebian S, et al. Attention demands of postural control in non-specific chronic low back pain subjects with low and high pain-related anxiety. Exp Brain Res. 2018;236:1927–1938.
   PubMed Web of Science ®Google Scholar
• Wang X, Xu Y, Chen X, et al. Dexmedetomidine inhibits osteosarcoma cell proliferation and migration, and promotes apoptosis by regulating miR-520a-3p. Oncol Res. 2018;26:495–502.
   PubMed Web of Science ®Google Scholar
• Palanichamy JK, Rao DS. miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet. 2014;5:54.
   PubMed Web of Science ®Google Scholar
• Yam C, He Y, Zhang D, et al. Divergent strategies for controlling the nuclear membrane satisfy geometric constraints during nuclear division. Curr Biol. 2011;21:1314–1319.
   PubMed Web of Science ®Google Scholar
• Xu YB, Du QH, Zhang MY, et al. Propofol suppresses proliferation, invasion and angiogenesis by down-regulating ERK-VEGF/MMP-9 signaling in Eca-109 esophageal squamous cell carcinoma cells. Eur Rev Med Pharmacol Sci. 2013;17:2486–2494.
   PubMed Web of Science ®Google Scholar
• Cai QH, Tang Y, Fan SH, et al. In vivo effects of dexmedetomidine on immune function and tumor growth in rats with ovarian cancer through inhibiting the p38MAPK/NF-kappaB signaling pathway. Biomed Pharmacother. 2017;95:1830–1837.
   PubMed Web of Science ®Google Scholar
• Tian H, Hou L, Xiong Y, et al. Effect of dexmedetomidine-mediated Insulin-Like Growth Factor 2 (IGF2) signal pathway on immune function and invasion and migration of cancer cells in rats with ovarian cancer. Med Sci Monit. 2019;14:94–106.
   Google Scholar
• Freitas M, Alves V, Sarmento-Ribeiro AB, et al. Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line. Biochem Biophys Res Commun. 2011;408:713–719.
   PubMed Web of Science ®Google Scholar
• Lv J, Liang Y, Tu Y, et al. Hypoxic preconditioning reduces propofol-induced neuroapoptosis via regulation of Bcl-2 and Bax and downregulation of activated caspase-3 in the hippocampus of neonatal rats. Neurol Res. 2018;40:767–773.
   PubMed Web of Science ®Google Scholar
• Peng X, Chen K, Chen J, et al. Aflatoxin B1 affects apoptosis and expression of Bax, Bcl-2, and Caspase-3 in thymus and bursa of fabricius in broiler chickens. Environ Toxicol. 2018;17(9):1742–1752.
   Google Scholar
• Liu M, Lang N, Chen X, et al. miR-185 targets RhoA and Cdc42 expression and inhibits the proliferation potential of human colorectal cells. Cancer Lett. 2011;301(2):151–160.
   PubMed Web of Science ®Google Scholar
• Imam JS, Buddavarapu K, Lee-Chang JS, et al. MicroRNA-185 suppresses tumor growth and progression by targeting the Six1 oncogene in human cancers. Oncogene. 2010;29:4971–4979.
   PubMed Web of Science ®Google Scholar
• Jiang SS, Fang WT, Hou YH, et al. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res. 2010;16:4363–4373.
   PubMed Web of Science ®Google Scholar
• Cai C, Wang H, He HH, et al. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest. 2013;123:1109–1122.
   PubMed Web of Science ®Google Scholar
• Li Y, Liu J, Piao J, et al. Circ_0109046 promotes the malignancy of endometrial carcinoma cells through the microRNA-105/SOX9/Wnt/beta-catenin axis. IUBMB Life. 2020;73(1):159–176.
   Web of Science ®Google Scholar
• Wall JA, Meza-Perez S, Scalise CB, et al. Manipulating the Wnt/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME tosensitize ovarian cancer to ICB therapy. Gynecol Oncol. 2021;160(1):285–294.
   PubMed Web of Science ®Google Scholar
• Jin X-T, Song L, Zhao J-Y, et al. Dichlorodiphenyltrichloroethane exposure induces the growth of hepatocellular carcinoma via Wnt/β-catenin pathway. Toxicol Lett. 2014;225(1):158–166.
   PubMed Web of Science ®Google Scholar
• Koehler A, Schlupf J, Schneider M, et al. Loss of Xenopus cadherin-11 leads to increased Wnt/β-catenin signaling and up-regulation of target genes c-myc and cyclin D1 in neural crest. Dev Biol. 2018;26(1):495–502.
   Google Scholar